
Opinion|Videos|March 19, 2024
Phase 2 Nivo/Cabo in Non-Clear Cell Renal Cell Carcinoma
Elizabeth Plimack, MD discusses recent results from the phase 2 nivolumab and cabozantinib trial in nccRCC.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
FDA Approves Liso-Cel as First CAR T-Cell Therapy for Marginal Zone Lymphoma
4
Poll Results Reveal Readers’ Top Abstracts at ASH 2025
5







































